التفاصيل البيبلوغرافية
العنوان:
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
المؤلفون:
Atefeh Bonyadi , Fariborz Mansour-Ghanaei , Farhang Babamahmoodi , Esmat Radmanesh , Hadiseh Hosamirudsari , Javad Khodadadi , Sara Sayar , Zeinab Mehrabi , Amir Reza Bahadori , Shahin Merat , Minoo Moghimi , Gholamali Eslami , Hashem Mousavi , Lotfollah Davoodi , Mona Ebrahimzadeh , Farahnaz Joukar , Amir Anushiravani , Ali Ali Asgari , Ali Reza Davoudi Badabi , Elham Barahimi , Saeed Jelvay , Zahra Poormontaseri , Aida Zeinali , Nasim Khajavirad , Minoosh Shabani , Hamideh Abbaspour Kasgari , Zohreh Azarkar , Rohollah Moslemi , Ahmad Hormati , Azadeh Ebrahimzadeh , Hani Esmaeilian , Shokrollah Salmanzadeh , Elham Akbarpour , Lili Rezaie Keikhaie , Kaitlyn McCann , Amir Mohammad Shabani , Abdolali Tousi , Mohammad Abdollahi , Sara Mobarak , Mohammadreza Naghipour , Hadi Mirzaei , Mohammadreza Salehi , Shervin Shokouhi , Bryony Simmons , Morteza Mobarak , Helia Nateghi Baygi , Jacob Levi , Mehdi Hassaniazad , Andrew Hill , Zahra Arizavi , Nasrollah Hasooni Bahrini , Seyed Ali Dehghan Manshadi , Fatemeh Dehghani , Hannah Wentzel , Hossein Pourmasoomi , Masoome Noori Jangi , Shoeleh Yaghoubi , Alireza Nateghi Baygi , Mehdi Salasi , Farnaz Zolfaghari , Sara Yeganeh , Elmira Azimi , Jalal Karimi , Hafez Fakheri , Mahdi Afshari , Tofigh Yaghubi Kalurazi , Anahita Sadeghi , Farshid Abedi , Sajedeh Mousaviasl , Zahra Nekoukar , Dorsa Merat , Masood Ziaee
المصدر:
Journal of Antimicrobial Chemotherapy
بيانات النشر:
Oxford University Press (OUP), 2021.
سنة النشر:
2021
مصطلحات موضوعية:
Adult , Microbiology (medical) , medicine.medical_specialty , Pyrrolidines , Randomization , Daclatasvir , Coronavirus disease 2019 (COVID-19) , Sofosbuvir , Placebo , Antiviral Agents , law.invention , Randomized controlled trial , law , Internal medicine , Clinical endpoint , AcademicSubjects/MED00740 , Humans , Medicine , Pharmacology (medical) , Original Research , Pharmacology , SARS-CoV-2 , business.industry , Imidazoles , COVID-19 , Valine , Institutional review board , Clinical trial , AcademicSubjects/MED00290 , Treatment Outcome , Infectious Diseases , Relative risk , Carbamates , AcademicSubjects/MED00230 , business , medicine.drug
الوصف:
Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and daclatasvir to standard care improved clinical endpoints in hospitalized patients with moderate or severe COVID-19. Methods: This was a placebo-controlled, randomized clinical trial in adults with moderate or severe COVID-19 admitted to 19 hospitals in Iran. Patients were randomized to SOF/DCV 400/60mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O 2 saturation
تدمد:
1460-2091
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69baf1a0987326edb8a47d694d9afe2Test https://doi.org/10.1093/jac/dkab433Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....f69baf1a0987326edb8a47d694d9afe2
قاعدة البيانات:
OpenAIRE
